

1 **Title:** Seroprevalence of chikungunya and o'nyong-nyong viruses in Senegal, West
2 Africa

3
4 Authors: Prince Baffour Tonto^{1,2}, Mouhamad Sy³, Ibrahima Mbaye Ndiaye³, Mariama
5 Toure³, Amy Gaye³, Mariama Aidara³, Amadou Moctar Mbaye³, Abdoulaye Kane Dia^{3,4},
6 Mamadou Alpha Diallo³, Jules Francois Gomis³, Mamadou Samba Yade³, Younous
7 Diedhiou³, Baba Dieye³, Khadim Diongue³, Mame Cheikh Seck³, Aida S. Badiane³,
8 Bobby Brooke Herrera^{1,2*}, Daouda Ndiaye³

9
10 **Affiliations:**

11 1 Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA

12 2 Department of Medicine, Division of Allergy, Immunology, and Infectious Diseases and
13 Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New
14 Brunswick, NJ, USA

15 3 International Research Training Center on Genomics and Health Surveillance
16 (CIGASS), Cheikh Anta Diop University, Dakar, 16477, Senegal

17 4 Laboratoire d'ecologie vectorielle et parasitaire

18

19 ***Corresponding Author:** BBH, bherrera@globalhealth.rutgers.edu

20

21

22

23 **Abstract**

24 **Background**

25 Arthritogenic alphaviruses such as chikungunya (CHIKV) and o'nyong-nyong (ONNV)
26 viruses have shown capacity to cause widespread epidemics, with recurrent and sporadic
27 outbreaks occurring throughout sub-Saharan Africa.

28 **Methods**

29 We analyzed the seroprevalence for CHIKV and ONNV in 470 non-febrile subjects from
30 three regions in Senegal (Sindia, 2018; Thies, 2018; and Kedougou, 2022/2023) using
31 retrospective samples. We assessed the presence of anti-CHIKV IgG and neutralizing
32 antibody titers against CHIKV and ONNV via enzyme-linked immunosorbent assay
33 (ELISA) and microneutralization tests, respectively, and determined risk factors of CHIKV
34 and ONNV exposure by binary logistic regression.

35 **Results**

36 The overall alphavirus seroprevalence based on an anti-CHIKV viral like particle (VLP)
37 IgG ELISA was 38.5%, with rates varying geographically: Kedougou (48.6%), Thies
38 (31.9%), and Sindia (14.9%). Neutralizing antibody titers revealed CHIKV and ONNV
39 seroprevalence rates of 7.4% and 9.8%, respectively, with significant variations by region
40 and age group. Cross-reactivity analysis showed that 82.9% of CHIKV cases exhibited a
41 neutralizing response to ONNV, while 71.7% of ONNV cases cross-neutralized CHIKV.
42 Residents of Thies had significantly higher odds of CHIKV infection (aOR, 3.147; 95% CI:
43 1.164-8.510) while ONNV infection was more likely in Kedougou (aOR, 3.888; 95% CI:
44 1.319-11.466). Furthermore, older age (> 40 years) was a significant risk factor both

45 CHIKV (aOR, 2.094; 95% CI: 0.846-5.185) and ONNV infection (aOR, 2.745; 95% CI:
46 1.212-6.216).

47 **Conclusions**

48 Our study confirms the co-circulation of CHIKV and ONNV in Senegal, highlighting their
49 geographic and demographic distribution. These findings underscore the need for
50 continued surveillance, alphavirus testing, and tailored public health strategies to mitigate
51 their impact in Senegal.

52

53

54

55

56

57

58

59

60

61

62

63 Introduction

64 Arboviruses transmitted by mosquitoes pose a growing global health threat,
65 significantly impacting morbidity and mortality. Among these, chikungunya (CHIKV) and
66 o'nyong-nyong (ONNV) viruses are notable members of the alphavirus genus, recognized
67 for their substantial effects on human health (1, 2). CHIKV, first isolated in Tanzania in
68 1952, has caused major outbreaks across Africa, Asia, and the Americas (3-5). Its
69 transmission primarily involves *Aedes* mosquitoes, and its capacity for widespread
70 dissemination was highlighted by the 2004 epidemic that originated in Kenya and rapidly
71 extended to various regions, including the Indian Ocean islands and South and Southeast
72 Asia (1, 5-7). By 2011, CHIKV reached the Western Hemisphere, spreading through the
73 Caribbean and South America by 2014, resulting in hundreds of thousands of infections
74 (8-10).

75 ONNV, identified in Uganda in 1959, has caused significant epidemics primarily in
76 East and West Africa, with major outbreaks recorded in the 1950s and early 1990s (11-
77 13). Transmitted by *Anopheles* mosquitoes, ONNV remains largely confined to the African
78 continent (6). The first major epidemic occurred from 1959 to 1962, affecting over 2 million
79 people across East and West Africa (14, 15). A subsequent outbreak from 1996 to 1997
80 primarily impacted Uganda, Kenya, and Tanzania, with infection rates ranging from 45-
81 68% (14, 16). Despite its geographical confinement, ONNV has been detected in travelers
82 returning from endemic regions (17).

83 Clinically, infections with CHIKV and ONNV are generally self-limiting but can
84 present a spectrum of symptoms including fever, arthralgia, rash, headache, and malaise
85 (18, 19). CHIKV is particularly associated with persistent arthralgia in patients (20).

86 Although ONNV is endemic to Africa, comprehensive data on its morbidity and mortality
87 are limited due to inadequate surveillance. The clinical features of alphavirus infections
88 closely resemble those caused by other pathogens including *Plasmodium* (malaria) or
89 *Salmonella* (typhoid fever) species, which are endemic in many West African countries
90 (21-26). This symptom overlap complicates diagnosis and can lead to underreporting of
91 CHIKV and ONNV, as their symptoms may be misattributed to other febrile illnesses.

92 In West Africa, including Senegal, autochthonous cases of CHIKV have been
93 reported since 1960, with periodic outbreaks continuing up to 2023 (27-31). Despite these
94 occurrences, current data on the seroprevalence of CHIKV and ONNV in Senegal
95 remains limited. This study aims to address this knowledge gap by investigating the
96 seroprevalence of CHIKV and ONNV in Senegal. Given the antigenic similarities between
97 these viruses, our approach focuses on using microneutralization assays to help
98 differentiate between them to provide a more in-depth understanding of their prevalence.
99 By enhancing our knowledge of the epidemiological landscape of CHIKV and ONNV in
100 Senegal, we hope to inform public health strategies and contribute valuable insights into
101 the broader context of arboviral transmission in West Africa.

102

103 **Methods**

104 **Study Population and Ethics Statement**

105 The samples included in our study were originally collected as part of malaria
106 and non-malarial surveillance among residents of Thies, Sindia, and Kedougou,
107 Senegal. Samples from Thies and Sindia were part of the surveillance of non-malarial
108 febrile illnesses, while samples from Kedougou were part of genomic surveillance of

109 malaria. Informed consent was obtained from all subjects and/or their legal guardians
110 for the initial sample collection as well as for its future use. All methods were performed
111 in accordance with the guidelines and regulations set forth by the Declaration of
112 Helsinki. The primary studies under which the samples and data were collected
113 received ethical clearance from the CIGASS Institutional Review Board (IRB) (Protocol
114 numbers: SEN15/46, 19300, and SEN14/49). All excess samples and corresponding
115 data were banked and de-identified prior to the analyses. This study received and
116 exemption determination from the Rutgers Robert Wood Johnson Medical School IRB.

117

118 **CHIKV viral like particle (VLP) ELISA**

119 CHIKV VLPs (20 ng per well; Native Antigen) were coated onto Nunc Maxisorp
120 96-well plates (ThermoFisher) overnight, followed by blocking (1X PBST, 1% BSA;
121 ThermoFisher) for 1 hour, then washing (1X PBST three times) and incubation with
122 primary antibodies for 2 hours (serum at 1:400 dilution) at room temperature. The plates
123 were washed three times with 1X PBST and bound sera were reacted with secondary
124 antibodies (anti-human IgG conjugated with horseradish peroxidase [HRP];
125 ThermoFisher), according to the manufacturer's instructions. The plates were washed
126 three more times and allowed to develop with 1-Step TMB ELISA Substrate
127 (ThermoFisher), according to the manufacturer's instructions. The OD at 450 nm was
128 read with a reference wavelength of 650 nm using an ELISA reader (Diasource). We
129 interpreted the ELISA assay as follows: 1) sample absorbance / negative control
130 absorbance ≤ 1.5 , negative; 2) sample absorbance / negative control absorbance > 1.5 ,
131 positive.

132

133 **Serum Microneutralization Assays**

134 Microneutralization assays were performed to detect neutralizing antibodies
135 against CHIKV and ONNV in samples that were IgG positive for CHIKV VLP. Sera were
136 diluted in a two-fold series from 1:40 to 1:10,240 in PBS in a 96-well plate. For each
137 dilution, contact was performed with 100 plaque forming units (PFU) of CHIKV (BEI
138 Resources: NR-56523) or ONNV (BEI Resources: NR-51661) for one hour at 37°C in a
139 5% CO₂ incubator. The complexes were then added to Vero cells (ATCC) CCL-81, 1.3 x
140 10⁵ cells per well. After 3-4 days of incubation, the cytopathogenic effects were
141 investigated by 0.2% crystal violet (SigmaAldrich) staining. After staining for 2-4 hours,
142 the plates were washed with copious amounts of tap water. For negative controls, at least
143 3 alphavirus-naïve serum samples were used to incubate with CHIKV or ONNV prior to
144 pipetting onto the Vero cells per plate. For positive controls, 100 PFU of CHIKV or ONNV
145 without any contact with serum were placed on Vero cells in triplicate per plate.

146 The neutralizing titer was defined as the inverse of the highest dilution resulting in
147 an infectious reduction of 50%. A titer lower than 1:40 was considered as negative if
148 cytopathogenic effects were not observed. Samples were considered as positive if the
149 titer was $\geq 1:40$, i.e., positive for ONNV if ONNV titers were at least two-fold higher than
150 CHIKV titers, and CHIKV positive if CHIKV titers were at least four-fold higher than ONNV
151 titers (32). The threshold was lower for ONNV than CHIKV because of the unique one-
152 way cross-reactivity between CHIKV and ONNV, i.e., CHIKV antibodies are more likely
153 to cross-react with ONNV antigens than ONNV antibodies with CHIKV antigens (33). All
154 other results were interpreted as equivocal. 20 Senegalese serum samples that were

155 previously determined to be alphavirus-naïve, were used to validate the assay. Each
156 assay used at least 4 alphavirus-naïve serum samples as negative controls.

157 **Statistical Analysis**

158 Categorical variables are represented as case counts and proportions, with
159 differences assessed using the Chi-square or Fisher exact test as appropriate. To
160 estimate the association between seroprevalence of alphavirus and demographics
161 factors, including age group, gender, city, a univariate binary logistic regression analysis
162 was performed. The adjusted odd ratios of the independent variables were computed by
163 adjusting for age and gender as confounding variables. Statistical analyses were
164 conducted using IBM SPSS statistics software version 28. The map of Senegal, heatmap,
165 and graph representing rates and percentages of CHIKV and ONNV neutralizing
166 antibodies were generated using R version 4.3.2 and Prism version 10.2.0.

167

168 **Results**

169 **Characteristics of study subjects**

170 A total of 470 samples collected from non-febrile subjects were included in the
171 study. These samples were collected from three locations in Senegal: Sindia (n=94),
172 Thies (n=94), and Kedougou (n=282). The samples from Sindia and Thies were malaria-
173 negative by rapid diagnostic testing, whereas the samples from Kedougou were from
174 subjects with malaria. The study population were relatively young, with approximately
175 48% of them aged 20 years or younger, and consisted of fewer females, comprising
176 44.89%. (Table 1).

177 Prevalence of CHIKV and ONNV

178 We first employed an anti-CHIKV VLP IgG ELISA to screen 470 non-febrile serum
179 samples. The CHIKV VLP antigen is specifically designed to detect IgG antibodies
180 against CHIKV but can also recognize cross-reactive antibodies against related
181 alphaviruses. Of the 470 samples tested, 181 were positive, resulting in an estimated
182 alphavirus prevalence of 38.5%. Seroprevalence rates varied by location. Sindia had a
183 rate of 14.9%, Thies had 31.9%, and Kedougou had 48.6% (Table 1).

184 Moreover, the microneutralization assay, regarded as the gold standard for
185 identifying prior exposure to a specific virus was utilized to differentiate exposure to
186 CHIKV and/or ONNV. Among the CHIKV IgG positive samples, 117 were available to
187 assess neutralizing antibodies against CHIKV and/or ONNV. The prevalence of
188 neutralizing antibodies against CHIKV and ONNV varied by location, gender, and age
189 group. The prevalence rates of CHIKV neutralizing antibodies were 6.4% in Sindia, 19.1%
190 in Thies, and 3.9% in Kedougou (Table 1). By gender, 7.0% for males and 8.0% for
191 females had CHIKV neutralizing antibodies (Table 2). Across age groups, the prevalence
192 was 7.6% in subjects aged ≤ 20 years, 5.3% in subjects aged 21 to 40 years, and 14.8%
193 in those over 40 years (Table 2). For ONNV, the neutralizing antibody prevalence rates
194 were 4.3% in Sindia, 4.3% in Thies, and 13.5% in Kedougou (Table 1). The prevalence
195 of ONNV neutralizing antibodies was 10.2% for males and 9.5% for females (Table 2).
196 Age-stratified prevalence showed a rate of 8.5 % in subjects aged ≤ 20 years, 8.0% in
197 subjects aged 21 to 40 years, and 20% in those over 40 years (Table 2).

198 Overall, 7.4% of the study subjects had neutralizing antibodies against CHIKV,
199 9.8% against ONNV, 5.1% were equivocal for both CHIKV and ONNV, and 2.6% were

200 negative, indicating prior exposure to other related alphaviruses (Table 1, Fig. 2A).
201 Moreover, of the subjects with CHIKV neutralizing antibodies, 82.9% had cross-
202 neutralizing antibodies against ONNV (Fig. 1B-C). However, subjects with ONNV
203 neutralizing antibodies, 71.7% had cross-neutralizing antibodies against CHIKV (Fig. 2B-
204 C).

205 Risk factors for CHIKV and ONNV infection

206 Univariate logistic regression, adjusted for age and gender, revealed that being a
207 resident of Thies (aOR, 2.384; 95% CI: 1.151-4.939) or Kedougou (aOR, 5.591; 95% CI:
208 3.001-10.418) were associated with increased odds of exposure to an alphavirus based
209 on IgG reactivity to CHIKV VLP, with the highest risk observed in Kedougou (S1 Table).
210 Modeling the presence of neutralizing antibodies to CHIKV against background factors
211 showed that subjects aged over 40 years had higher odds of CHIKV infection after
212 adjusting for age and gender (aOR, 2.094; 95% CI: 0.846-5.185), though this association
213 was marginally significant (Table 3). Additionally, the prevalence of CHIKV neutralizing
214 antibodies was higher in subjects aged over 40 years compared to the other age groups
215 (Fig 1A). Furthermore, subjects from Thies were more likely to be infected with CHIKV
216 (aOR, 3.147; 95% CI: 1.164-8.510) (Table 3), with a significantly higher prevalence of
217 CHIKV neutralizing antibodies in this city compared to Sindia and Kedougou (Fig 1B).
218 Residence of Kedougou was associated with significantly lower odds of contracting
219 CHIKV (aOR, 0.606; 95% CI: 0.217-1.692) (Table 3).

220 For ONNV, univariate analysis, adjusted for age and gender, revealed that
221 subjects aged over 40 years (aOR, 2.745; 95% CI: 1.212-6.216) had significantly
222 increased odds of infection (Table 3), with a significantly higher prevalence of ONNV

223 neutralizing antibodies in this age group compared to the other age groups (Fig 1A).
224 Subjects aged 21 to 40 (aOR, 0.682; 95% CI: 0.304-1.531) years were associated with
225 lower odds of ONNV infection (Table 3). Being a resident of Kedougou (aOR, 3.888; 95%
226 CI: 1.319-11.466) was associated with increase odds of ONNV infection (Table 3), with
227 significantly higher prevalence of ONVV neutralizing antibodies compared to the other
228 cities (Fig 2B). Residence from Thies was associated with lower odds of infection (aOR,
229 0.764; 95% CI: 0.179-3.256) (Table 3).

230

231 Discussion

232 In this study, we observed an overall alphavirus prevalence of 38.5% with notable
233 geographical variations. Virus-specific analysis revealed prevalence rates of 7.4% for
234 CHIKV exposure and 9.8% for ONNV, both exhibiting significant geographical and age-
235 related variations. Cross-reactivity analysis showed that 82.9% of CHIKV cases exhibited
236 a neutralizing response to ONNV, while 71.7% of ONNV cases cross-neutralized CHIKV.
237 Older age emerged as a significant risk factor for ONNV exposure, and to a lesser extent
238 CHIKV. Additionally, ONNV exposure was significantly associated with residence in
239 Kedougou, while CHIKV exposure was strongly linked to residence in Thies. These
240 findings emphasize the continued transmission of alphaviruses in Senegal, specifically
241 CHIKV and ONNV, driven by geographic location as well as age-susceptibility.

242 The first documentation of a CHIKV human infection dates back to 1966 in
243 Rufisque, a city near Dakar, as part of arbovirus surveillance programs led by the Institut
244 Pasteur de Dakar. During this surveillance, CHIKV was detected in both mosquito vectors

245 and in human populations (29). Since then, numerous reports have documented CHIKV
246 circulation in the country, highlighting its endemicity and periodic re-emergence. A notable
247 example is the recent outbreak of CHIKV in Kedougou, which was attributed to the re-
248 emergence of an endemic strain (27).

249 To date, seroprevalence studies aimed at understanding CHIKV circulation in
250 Senegal have predominantly relied on detecting anti-CHIKV IgG antibodies using ELISA
251 (34, 35). However, this approach tends to overestimate CHIKV prevalence due to the
252 significant cross-reactivity between CHIKV and related alphaviruses, particularly ONNV.
253 This limitation highlights the need for more specific diagnostic methods, such as virus
254 neutralization assays or molecular techniques, to accurately discern CHIKV exposure and
255 better differentiate it from other co-circulating alphaviruses. Consequently, the use of a
256 microneutralization assay in this study allowed us to identify subjects with specific or
257 cross-reactive responses to either CHIKV or ONNV, providing a more accurate
258 assessment of their respective seroprevalence rates.

259 The prevalence rates for CHIKV and ONNV observed in our study differs from
260 those reported in similar studies in Senegal and other countries. For instance, a recent
261 study in Kedougou, involving inhabitants of 120 randomly selected villages, reported a
262 CHIKV prevalence of 54% (35), which is higher than both our overall observed rate and
263 the prevalence among the subjects from Kedougou in our study. An explanation for the
264 higher rate in this study is likely due to implementation of an anti-CHIKV IgG ELISA, which
265 measures cross-reactive alphavirus antibodies. In Nigeria, a systematic review
266 encompassing published literature spanning four decades reported a CHIKV prevalence
267 of 46.1% (36) based on neutralizing antibodies, a rate higher than that observed in the

268 present study. Additionally, our observed CHIKV prevalence rate is lower than the 56.5%
269 (37) reported among blood donors in Burkina Faso. Conversely, a study conducted in
270 Kenya reported CHIKV prevalence of 9.8% (38) among children from four communities
271 within the coastal and western regions, a rate comparable to our findings.

272 For ONNV, the prevalence rate observed in our study is lower than the 54.5% (37)
273 reported among blood donors in Burkina Faso, and the 28.4% (39) reported among HIV
274 patients in Madagascar. Importantly, both studies used anti-CHIKV IgG ELISAs to
275 measure antibody responses, which may have skewed the higher rates. Additionally,
276 modeling studies in Mali, using serological data estimated an ONNV prevalence of 30%
277 (33), also exceeding our observed rate. These discrepancies may be attributed to
278 differences in study population, sample size, methodological approaches, and ecological
279 or environment factors that influence virus transmission.

280 Our univariate logistic regression analysis identified older age as a risk factor for
281 both CHIKV and ONNV infection. We observed a higher prevalence of neutralizing
282 antibodies for both viruses in the older age group compared to their younger counterparts,
283 corroborating the notion that cumulative exposure over time contributes to higher
284 exposure rates. This demographic insight is crucial for developing targeted public health
285 strategies, especially for vaccine deployment and vector control initiatives. The
286 identification of older age as a risk factor for CHIKV infection is consistent with similar
287 findings from a study in Burkina Faso (37).

288 Furthermore, residents of Thies showed a three-fold increase in the likelihood of
289 CHIKV infection compared to other regions, as evidenced by the higher prevalence of
290 CHIKV neutralizing antibodies in Thies. Conversely, residents of Kedougou showed a

291 four-fold increase in the likelihood of ONNV infection, as evidenced by higher prevalence
292 of ONNV neutralizing antibodies compared to the other regions. These regional
293 differences may be attributed to distinct local vector ecologies or differences in human
294 activities that increase exposure to virus-specific mosquito vectors. These hypotheses
295 require further research.

296 We also observed that the prevalence of cross-neutralizing antibodies against
297 ONNV was higher among subjects with CHIKV neutralizing antibodies compared to those
298 with ONNV neutralizing antibodies exhibiting cross-neutralization against CHIKV. These
299 findings corroborate a directional bias in immune cross-reactivity, where CHIKV exposure
300 might confer broader immunity, potentially impacting subsequent ONNV infection
301 dynamics (33). This asymmetric cross-reactivity could also be due to structural similarities
302 in the viral envelope proteins of CHIKV and ONNV, with CHIKV eliciting a broader
303 neutralizing response (33). This phenomenon is crucial for diagnostic tests, which may
304 need differentiation between past infections of these two viruses based on neutralizing
305 antibody profiles. Moreover, understanding the mechanisms behind this differential cross-
306 reactivity could guide vaccine strategies where a vaccine against one virus might offer
307 partial protection against the other, hence optimizing the control measures for both
308 viruses in regions where they co-circulate.

309 One of the strengths of this study is our robust delineation of subjects previously
310 exposed to CHIKV or ONNV in Senegal, achieved through the use of neutralization
311 assays to minimize cross-reactivity. This methodological rigor makes our study the first
312 to report the co-circulation of these antigenically related viruses in the country, providing
313 valuable insights into their epidemiology and the public health risks they pose.

314 Despite its strengths, our study has several limitations. Of the 180 samples positive
315 for alphavirus IgG by ELISA, we were only able to perform neutralization assays on 117
316 due to sample availability. This limitation likely led to an underestimation of the true
317 prevalence of CHIKV and ONNV in our study populations. Additionally, while our use of
318 neutralization assays minimized cross-reactivity compared to the ELISA, a large
319 percentage of samples were considered equivocal, consistent with findings from other
320 studies. In contrast, other studies that rely solely on ELISA often classify these equivocal
321 results as positive, leading to potential overestimations of CHIKV prevalence (34, 35, 37).
322 Our approach provides a more conservative and potentially accurate estimate but
323 underscores the need for improved diagnostic tools to address the challenge of equivocal
324 results in alphavirus seroprevalence studies. Moreover, without concurrent clinical data,
325 we also cannot definitively link our serological findings to symptomatic disease cases,
326 underestimating the true burden of these infections. Additionally, the insights into antibody
327 cross-reactivity are essential for the interpretation of seroprevalence data in regions
328 endemic to both viruses, as they could lead to overestimations of immunity against one
329 virus due to past exposure to the other. This is particularly relevant in vaccine efficacy
330 trials and in the evaluation of natural immunity in the population.

331 Conclusions drawn from our research illustrate the persistent circulation of CHIKV
332 and ONNV in Senegal, necessitating sustained surveillance and public health
333 preparedness to mitigate the impact of these and other arboviruses. The findings also
334 emphasize the importance of ecological and demographic factors in shaping the
335 epidemiology of these diseases, highlighting the need for comprehensive arbovirus
336 control strategies that integrate vector management with community health initiatives.

337 Future studies should aim to incorporate entomological and clinical data to provide a more
338 holistic understanding of the transmission dynamics and to facilitate the development of
339 targeted interventions, including vaccines and therapeutic measures.

340

341 **Acknowledgements**

342 We would like to thank Rutgers Global Health Institute, Rutgers Robert Wood Johnson
343 Medical School, and the Child Health Institute of New Jersey.

344

345 **Conflicts of Interest**

346 BBH is a co-founder of Mir Biosciences, Inc., a biotechnology company that develops
347 diagnostics and vaccines for infectious diseases, cancer, and autoimmunity.

348

349 **Author Contributions**

350 Conceptualization: BBH

351 Data curation: PBT, MS, IMN, MT, AG, MA, BBH, DN

352 Formal analysis: PBT, MS, IMN, MT, AG, MA, BBH, DN

353 Funding acquisition: BBH, DN

354 Investigation: PBT, MS, IMN, MT, AG, MA, BBH, DN

355 Methodology: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,

356 MCS, ASB, BBH, DN

357 Project administration: BBH, DN

358 Resources: BBH, DN
359 Software: PBT, MS, BBH
360 Supervision: BBH, MS, DN
361 Validation: PBT, MS, IMN, MT, AG, MA, BBH, DN
362 Visualization: PBT, MS, IMN, MT, AG, MA, BBH, DN
363 Writing – original draft: PBT, BBH
364 Writing – review & editing: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY,
365 YD, BD, KD, MCS, ASB, BBH, DN
366

367 **References**

- 368 1. Pezzi L, LaBeaud AD, Reusken CB, Drexler JF, Vasilakis N, Diallo M, et al.
369 GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2:
370 Epidemiological distribution of o'nyong-nyong virus. *Antiviral Res.* 2019;172:104611.
- 371 2. Zaid A, Burt FJ, Liu X, Poo YS, Zandi K, Suhrbier A, et al. Arthritogenic
372 alphaviruses: epidemiological and clinical perspective on emerging arboviruses. *Lancet*
373 *Infect Dis.* 2021;21(5):e123-e33.
- 374 3. Renault P, Balleydier E, D'Ortenzio E, Baviile M, Filleul L. Epidemiology of
375 Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. *Med Mal*
376 *Infect.* 2012;42(3):93-101.
- 377 4. Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus:
378 mapping the 64-year history. *Int J Infect Dis.* 2017;58:69-76.
- 379 5. Zeller H, Van Bortel W, Sudre B. Chikungunya: Its History in Africa and Asia and
380 Its Spread to New Regions in 2013-2014. *J Infect Dis.* 2016;214(suppl 5):S436-S40.

- 381 6. Pezzi L, Diallo M, Rosa-Freitas MG, Vega-Rua A, Ng LFP, Boyer S, et al.
382 GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 5:
383 Entomological aspects. *Antiviral Res.* 2020;174:104670.
- 384 7. Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, et al.
385 Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya,
386 October 2004. *Am J Trop Med Hyg.* 2008;78(2):333-7.
- 387 8. Fischer M, Staples JE, Arboviral Diseases Branch NCfE, Zoonotic Infectious
388 Diseases CDC. Notes from the field: chikungunya virus spreads in the Americas -
389 Caribbean and South America, 2013-2014. *MMWR Morb Mortal Wkly Rep.*
390 2014;63(22):500-1.
- 391 9. Manzoor KN, Javed F, Ejaz M, Ali M, Mujaddadi N, Khan AA, et al. The global
392 emergence of Chikungunya infection: An integrated view. *Rev Med Virol.*
393 2022;32(3):e2287.
- 394 10. Teixeira MG, Andrade AM, Costa Mda C, Castro JN, Oliveira FL, Goes CS, et al.
395 East/Central/South African genotype chikungunya virus, Brazil, 2014. *Emerg Infect Dis.*
396 2015;21(5):906-7.
- 397 11. Corbet PS, Williams MC, Gillett JD. O'Nyong-Nyong fever: an epidemic virus
398 disease in East Africa. IV. Vector studies at epidemic sites. *Trans R Soc Trop Med Hyg.*
399 1961;55:463-80.
- 400 12. Williams MC, Woodall JP, Corbet PS, Gillett JD. O'nyong-Nyong Fever: An
401 Epidemic Virus Disease in East Africa. 8. Virus Isolations from Anopheles Mosquitoes.
402 *Trans R Soc Trop Med Hyg.* 1965;59:300-6.

- 403 13. Lanciotti RS, Ludwig ML, Rwaguma EB, Lutwama JJ, Kram TM, Karabatsos N,
404 et al. Emergence of epidemic O'nyong-nyong fever in Uganda after a 35-year absence:
405 genetic characterization of the virus. *Virology*. 1998;252(1):258-68.
- 406 14. Rezza G, Chen R, Weaver SC. O'nyong-nyong fever: a neglected mosquito-
407 borne viral disease. *Pathog Glob Health*. 2017;111(6):271-5.
- 408 15. Williams MC, Woodall JP, Gillett JD. O'nyong-Nyong Fever: An Epidemic Virus
409 Disease in East Africa. Vii. Virus Isolations from Man and Serological Studies up to
410 July 1961. *Trans R Soc Trop Med Hyg*. 1965;59:186-97.
- 411 16. Kiwanuka N, Sanders EJ, Rwaguma EB, Kawamata J, Ssengooba FP, Najjemba
412 R, et al. O'nyong-nyong fever in south-central Uganda, 1996-1997: clinical features and
413 validation of a clinical case definition for surveillance purposes. *Clin Infect Dis*.
414 1999;29(5):1243-50.
- 415 17. Tappe D, Kapaun A, Emmerich P, Campos Rde M, Cadar D, Gunther S, et al.
416 O'nyong-nyong virus infection imported to Europe from Kenya by a traveler. *Emerg*
417 *Infect Dis*. 2014;20(10):1766-7.
- 418 18. Johnson BK. O'nyong-nyong virus disease. *Arboviruses: CRC Press*; 2019. p.
419 217-24.
- 420 19. Kucharz EJ, Cebula-Byrska I. Chikungunya fever. *Eur J Intern Med*.
421 2012;23(4):325-9.
- 422 20. Schilte C, Staikovsky F, Couderc T, Madec Y, Carpentier F, Kassab S, et al.
423 Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal
424 study. *PLoS neglected tropical diseases*. 2013;7(3):e2137.

- 425 21. Al-Emran HM, Eibach D, Krumkamp R, Ali M, Baker S, Biggs HM, et al. A
426 multicountry molecular analysis of *Salmonella enterica* serovar Typhi with reduced
427 susceptibility to ciprofloxacin in sub-Saharan Africa. *Clinical Infectious Diseases*.
428 2016;62(suppl_1):S42-S6.
- 429 22. Badiane AS, Ngom B, Ndiaye T, Cunningham D, Campbell J, Gaye A, et al.
430 Evidence of *Plasmodium vivax* circulation in western and eastern regions of Senegal:
431 implications for malaria control. *Malaria Journal*. 2024;23(1):149.
- 432 23. Diallo A, Sié A, Sirima S, Sylla K, Ndiaye M, Bountogo M, et al. An
433 epidemiological study to assess *Plasmodium falciparum* parasite prevalence and
434 malaria control measures in Burkina Faso and Senegal. *Malaria journal*. 2017;16:1-12.
- 435 24. Diallo M, Diongue K, Diagne G, Seck M, Ndiaye M, Dièye B, et al. *Plasmodium*
436 *ovale wallikeri* and *Plasmodium ovale curtisi* Malaria in Senegal in 2016. *Bulletin de la*
437 *Société de pathologie exotique*. 2017;110:286-90.
- 438 25. Dromigny J-A, Perrier-Gros-Claude J-D. Antimicrobial resistance of *Salmonella*
439 *enterica* serotype Typhi in Dakar, Senegal. *Clinical infectious diseases*. 2003;37(3):465-
440 6.
- 441 26. Harrois D, Breurec S, Seck A, Delauné A, Le Hello S, de La Gandara MP, et al.
442 Prevalence and characterization of extended-spectrum β -lactamase-producing clinical
443 *Salmonella enterica* isolates in Dakar, Senegal, from 1999 to 2009. *Clinical*
444 *Microbiology and Infection*. 2014;20(2):O109-O16.
- 445 27. Dieng I, Sadio BD, Gaye A, Sagne SN, Ndione MHD, Kane M, et al. Genomic
446 characterization of a reemerging Chikungunya outbreak in Kedougou, Southeastern
447 Senegal, 2023. *Emerg Microbes Infect*. 2024;13(1):2373308.

- 448 28. Pistone T, Ezzedine K, Boisvert M, Receveur MC, Schuffenecker I, Zeller H, et
449 al. Cluster of chikungunya virus infection in travelers returning from Senegal, 2006. *J*
450 *Travel Med.* 2009;16(4):286-8.
- 451 29. Roche S, Robin Y. [Human infections by Chikungunya virus in Rufisque
452 (Senegal), October-November, 1966]. *Bull Soc Med Afr Noire Lang Fr.* 1967;12(3):490-
453 6.
- 454 30. Saluzzo J, Cornet M, Digoutte J. Outbreak of a Chikungunya virus epidemic in
455 western Senegal in 1982. *Dakar medical.* 1983;28(3):497-500.
- 456 31. Sow A, Faye O, Diallo M, Diallo D, Chen R, Faye O, et al. Chikungunya Outbreak
457 in Kedougou, Southeastern Senegal in 2009-2010. *Open Forum Infect Dis.*
458 2018;5(1):ofx259.
- 459 32. LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, et al.
460 High rates of o'nyong nyong and Chikungunya virus transmission in coastal Kenya.
461 *PLoS Negl Trop Dis.* 2015;9(2):e0003436.
- 462 33. Hoze N, Diarra I, Sangare AK, Pastorino B, Pezzi L, Kouriba B, et al. Model-
463 based assessment of Chikungunya and O'nyong-nyong virus circulation in Mali in a
464 serological cross-reactivity context. *Nat Commun.* 2021;12(1):6735.
- 465 34. de Souza WM, Gaye A, Ndiaye EH, Morgan AL, Sylla EHD, Sy FA, et al.
466 Serosurvey of Chikungunya Virus in Old World Fruit Bats, Senegal, 2020-2022. *Emerg*
467 *Infect Dis.* 2024;30(7):1490-2.
- 468 35. Sow A, Nikolay B, Faye O, Cauchemez S, Cano J, Diallo M, et al. Changes in the
469 Transmission Dynamic of Chikungunya Virus in Southeastern Senegal. *Viruses.*
470 2020;12(2).

- 471 36. Abdullahi IN, Akande AO, Muhammed Y, Rogo LD, Oderinde BS. Prevalence
472 Pattern of Chikungunya Virus Infection in Nigeria: A Four Decade Systematic Review
473 and Meta-analysis. *Pathog Glob Health*. 2020;114(3):111-6.
- 474 37. Tinto B, Bicaba B, Kagoné TS, Kayiwa J, Rabe I, Merle CSC, et al. Co-circulation
475 of two Alphaviruses in Burkina Faso: Chikungunya and O'nyong nyong viruses. *PLoS*
476 *Negl Trop Dis*. 2024;18(6):e0011712.
- 477 38. Khan A, Bisanzio D, Mutuku F, Ndenga B, Grossi-Soyster EN, Jembe Z, et al.
478 Spatiotemporal overlapping of dengue, chikungunya, and malaria infections in children
479 in Kenya. *BMC Infect Dis*. 2023;23(1):183.
- 480 39. Rakotomalala FA, Bouillin J, Randriarimanana SD, Thaurignac G, Maharavo L,
481 Raberahona M, et al. High Seroprevalence of IgG Antibodies to Multiple Arboviruses in
482 People Living with HIV (PLWHIV) in Madagascar. *Viruses*. 2023;15(11).
- 483
- 484
- 485
- 486
- 487
- 488
- 489
- 490
- 491
- 492
- 493

494 **Tables**

495

496 **Table 1. Baseline characteristics and chikungunya virus (CHIKV) and o’nyong-**
 497 **nyong virus (ONNV) serology**

	Sindia (n=94)	Thies (n=94)	Kedougou (n=282)	Total (n=470)
Demographics				
Year(s) samples collected	2018	2018	2022-2023	
Age group, n (%)				
≤ 20 years	40 (42.6)	48 (41.1)	136 (48.2)	224 (47.7)
21-40 years	42 (44.7)	23 (24.4)	123 (43.6)	188 (40.0)
> 40 years	11 (11.7)	23 (24.4)	21 (7.5)	55 (11.7)
Unreported	1 (1.0)	—	2 (0.7)	3 (0.6)
Female gender, n (%)	39 (41.5)	51 (54.3)	121 (42.9)	211 (44.9)
History of malaria infection, n (%)	0 (0)	0 (0)	282 (100)	282 (60)
Serology				
CHIKV VLP IgG+, n (%)	14 (14.9)	30 (31.9)	137 (48.6)	181 (38.5)
NT50, n (%)				
CHIKV	6 (6.4)	18 (19.1)	11 (3.9)	35 (7.4)
ONNV	4 (4.3)	4 (4.3)	38 (13.5)	46 (9.8)
Equivocal	4 (4.3)	5 (5.3)	15 (5.3)	24 (5.1)
Negative	0 (0.0)	0 (0.0)	12 (4.3)	12 (2.6)

498

499

500

501

502

503

504 **Table 2. Baseline characteristics of NT50-confirmed chikungunya virus (CHIKV)**
505 **and o'nyong-nyong virus (ONNV) subjects**

	Total n= 470	CHIKV NT50- confirmed subjects n=35	ONNV NT50- confirmed subjects n=46
Age group, n (%)			
≤ 20 years	224 (47.7)	17 (7.6)	19 (8.5)
21-40 years	188 (40.0)	10 (5.3)	15 (8.0)
> 40 years	55 (11.7)	8 (14.8)	11 (20.0)
Unreported	3 (0.6)	0 (0.0)	1 (33.3)
Gender, n (%)			
Male	256 (54.5)	18 (7.0)	26 (10.2)
Female	211 (44.9)	17 (8.0)	20 (9.5)
Unreported	3 (0.6)	0 (0.0)	0 (0.0)
City, n (%)			
Sindia	94 (20.0)	6 (6.4)	4 (4.3)
Thies	94 (20.0)	18 (19.1)	4 (4.3)
Kedougou	282 (60.0)	11 (3.9)	38 (13.5)
History of malaria infection, n (%)			
	282 (60)	11 (3.9)	38 (13.5)

506

507

508

509

510

511

512

513

514

515


516 **Table 3. Risk factors for chikungunya virus (CHIKV) and o'nyong-nyong virus**
 517 **(ONNV) infections in Senegal**

Predictor	Univariate binary logistic regression			
	OR (95% CI)	p value	aOR (95% CI)	p value
CHIKV NT50-confirmed subjects				
Age group				
≤ 20 years	Reference	0.077	Reference	0.082
21-40 years	0.687 (0.307-1.539)		0.682 (0.304-1.531)	
> 40 years	2.128 (0.866-5.228)		2.094 (0.846-5.185)	
Gender				
Male	Reference		Reference	
Female	1.153 (0.579-2.297)	0.686	1.100 (0.546-2.213)	0.79
City				
Sindia	Reference	<0.001	Reference	<0.001
Thies	3.474 (1.312-9.196)		3.147 (1.164-8.510)	
Kedougou	0.595 (0.214-1.657)		0.606 (0.217-1.692)	
ONNV NT50-confirmed subjects				
Age group				
≤ 20 years	Reference	0.027	Reference	0.026
21-40 years	0.936 (0.462-1.896)		0.948 (0.467-1.924)	
> 40 years	2.697 (1.199-6.068)		2.745 (1.212-6.216)	
Gender				
Male	Reference		Reference	
Female	0.926 (0.501-1.711)	0.807	0.897 (0.478-1.683)	0.736
City				
Sindia	Reference	0.008	Reference	0.002
Thies	1.000 (0.243-4.122)		0.764 (0.179-3.256)	
Kedougou	3.504 (1.216-10.096)		3.888 (1.319-11.466)	

OR- Crude odd ratio; aOR- adjusted odd ratio for gender and age

518
519

520 Figures



521

522 **Fig 1. Comparison of the prevalence of neutralizing antibodies to CHIKV and ONNV**

523 **by age group, city, and gender.** Differences between (A) age, (B) city, and (C) gender

524 were assessed using the Chi-square test or Fisher's exact test, as appropriate. P-values

525 less than 0.05 were considered to be statistically significant, while values less than 0.1

526 were considered to be marginally significant.

527

528

529

530

531

532


533

534

535

536

537



538

539 **Fig. 2. Antibody neutralization against chikungunya (CHIKV) and o'nyong-nyong**

540 **(ONNV) viruses in Senegal. (A)** Map depicts locations in Senegal (Sindia, Thies, and

541 Kedougou) where samples were collected from non-febrile subjects. For each location,

542 bar charts represent the neutralizing antibody prevalence against CHIKV (C) or ONNV

543 (C), or equivocal (E) and negative (N) results. Prevalence values are listed above each

544 bar. (B) CHIKV virus-like particle IgG-positive samples (n=117) were tested for

545 neutralizing antibodies against CHIKV and ONNV. Colors depict the 50% neutralizing

546 antibody titers (NT50), each row represents one individual, and each column is the titer

547 to CHIKV or ONNV. (C) The percentage of NT50-confirmed CHIKV or ONNV subjects

548 with cross-neutralizing antibodies to the heterologous virus.